UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome

Annals of oncology, 2012-06, Vol.23 (6), p.1640-1645

2012

Volltextzugriff (PDF)

OP29 Therapy of Hodgkin's lymphoma in MDACC

Leukemia research, 2007, Vol.31, p.S46-S46

Hagemeister, F.B

2007

Volltextzugriff (PDF)

Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non Hodgkin Lymphoma

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.S79-S80

2015

Volltextzugriff (PDF)

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes

Annals of oncology, 2015-06, Vol.26 (6), p.1175-1179

2015

Volltextzugriff (PDF)

Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms

Blood, 2021-11, Vol.138 (Supplement 1), p.2395-2395

2021

Volltextzugriff (PDF)

Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma

Blood, 2019-11, Vol.134 (Supplement_1), p.1533-1533

2019

Volltextzugriff (PDF)

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Blood, 2018-11, Vol.132 (Supplement 1), p.447-447

2018

Volltextzugriff (PDF)

Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R2) in Previously Untreated Follicular Lymphoma

Blood, 2018-11, Vol.132 (Supplement 1), p.1594-1594

2018

Volltextzugriff (PDF)

Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) - Response and Clinical Outcomes in Ultra-Refractory MCL

Blood, 2019-11, Vol.134 (Supplement_1), p.2815-2815

2019

Volltextzugriff (PDF)

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes

Annals of oncology, 2016-07, Vol.27 (7), p.1317-1323

2016

Volltextzugriff (PDF)

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era

Annals of oncology, 2016-05, Vol.27 (5), p.895-901

2016

Volltextzugriff (PDF)

Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib

Blood, 2018-11, Vol.132 (Supplement 1), p.4151-4151

2018

Volltextzugriff (PDF)

Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma

Blood, 2018-11, Vol.132 (Supplement 1), p.96-96

2018

Volltextzugriff (PDF)

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Blood, 2019-11, Vol.134 (Supplement_1), p.3987-3987

2019

Volltextzugriff (PDF)

Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types

Blood, 2018-11, Vol.132 (Supplement 1), p.3356-3356

2018

Volltextzugriff (PDF)

Bone mineral density screening should be routine in lymphoma patients

Annals of oncology, 2014-04, Vol.25 (4), p.913-914

2014

Volltextzugriff (PDF)

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

Blood, 2017-12, Vol.130, p.4040-4040

2017

Volltextzugriff (PDF)

A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas

Blood, 2017-12, Vol.130, p.4074-4074

2017

Volltextzugriff (PDF)

Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results

Blood, 2017-12, Vol.130, p.189-189

2017

Volltextzugriff (PDF)

TREATMENT WITH COMBINATION OF LENALIDOMIDE AND RITUXIMAB ACHIEVES DURABLE RESPONSES IN A LONG TERM FOLLOW UP OF PATIENTS WITH INDOLENT NON‐HODGKIN'S LYMPHOMA

Hematological oncology, 2017-06, Vol.35 (S2), p.215-216

2017

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(71)

Sprache

Englisch
(71)

Erscheinungsjahr

n.n

Thema

Humans
(29)
Life Sciences & Biomedicine
(25)
Science & Technology
(25)
Adult
(24)
Male
(24)
Female
(23)
Middle Aged
(22)
Biological And Medical Sciences
(21)
Medical Sciences
(21)
Oncology
(21)
Aged
(18)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(16)
Pharmacology. Drug Treatments
(13)
Vincristine - Administration & Dosage
(13)
Antineoplastic Agents
(12)
Prednisone - Administration & Dosage
(12)
Hodgkin Disease - Drug Therapy
(11)
Prognosis
(11)
Combined Modality Therapy
(10)
Doxorubicin - Administration & Dosage
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome

OP29 Therapy of Hodgkin's lymphoma in MDACC

Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non Hodgkin Lymphoma

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma

Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms

Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R2) in Previously Untreated Follicular Lymphoma

Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) - Response and Clinical Outcomes in Ultra-Refractory MCL

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes

Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma - Cohort Study of 369 Patients

Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era

Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib

Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types

Bone mineral density screening should be routine in lymphoma patients

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas

Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results

Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience

TREATMENT WITH COMBINATION OF LENALIDOMIDE AND RITUXIMAB ACHIEVES DURABLE RESPONSES IN A LONG TERM FOLLOW UP OF PATIENTS WITH INDOLENT NON‐HODGKIN'S LYMPHOMA

Suchergebnisse filtern